The Uromigos
Episodes
Episode 489: Live Podcast From EAU
16 Mar 2026
Contributed by Lukas
Tom and Brian take the stage in London for a live podcast. With the help of several special guests from the audience, they discuss management of peri-...
Episode 488: Uromigos Japan - ASCO GU26速報！尿路上皮がん
15 Mar 2026
Contributed by Lukas
周術期EV+PembroのKEYNOTE-B15試験をはじめとして、大きな話題が多かった今年のASCOGU。結果の解釈から今後の臨床への...
Episodio 485: ASCO GU 2026 - LITESPARK 011: Len/Belzutifan vs Cabo
10 Mar 2026
Contributed by Lukas
En este episodio se abordan los resultados más recientes del ensayo fase 3 LITESPARK 011 (belzutifan + lenvatinib frente a cabozantinib). Brian, Tom ...
Episodio 484: ASCO GU 2026 - LITESPARK 022: Pembro adyuvante + Belzutifan en cáncer renal
10 Mar 2026
Contributed by Lukas
En esta discusión se exploran los últimos avances en el tratamiento adyuvante del cáncer de riñón, centrándose en los recientes resultados del e...
Episodio 483: ASCO GU 2026 - KEYNOTE B15: EVP neoadyuvante vs Gem/Cis en cáncer de vejiga músculo-invasivo cisplatino elegible
10 Mar 2026
Contributed by Lukas
En este episodio, Brian, Tom y Matt Galsky analizan los datos del estudio B15 sobre terapia neoadyuvante para el cáncer de vejiga músculo-invasivo c...
Episodio 482: ASCO GU 2026 - SUNRISE 2
10 Mar 2026
Contributed by Lukas
La conversación gira en torno al ensayo Sunrise 2, un estudio que investiga la eficacia de TAR-200 combinado con cetrilimab frente a quimiorradiotera...
Episodio 480: ASCO GU 2026 - Resultados finales de SG de PEACE-3 y BRCAway
10 Mar 2026
Contributed by Lukas
En este episodio, Evan Yu analiza los datos más recientes sobre cáncer de próstata presentados en ASCO GU, centrándose en los resultados finales d...
Episode 487: ASCO GU 2026 recap
08 Mar 2026
Contributed by Lukas
Brian, Silke and Tom discusses the latest data and insights from ASCO GU 2026 across kidney, prostate, and bladder cancer, highlighting new therapies,...
Episode 486: ctDNA and utDNA Data in Peri-operative Urothelial cancer
04 Mar 2026
Contributed by Lukas
summaryThis episode explores the latest advances in circulating tumor DNA (ctDNA) and urinary tumor DNA (utDNA) in bladder cancer management. Experts...
Episode 485: ASCO GU 2026 - LITESPARK 011: Len/Belzu vs Cabo
28 Feb 2026
Contributed by Lukas
summaryThis detailed discussion covers the latest phase three trial results in kidney cancer, focusing on LITESPARK 011: Belzutifan and Levatnib comb...
Episode 484: ASCO GU 2026 - LITESPARK 022: Adjuvant Pembro + Belzutifan in RCC
28 Feb 2026
Contributed by Lukas
This in-depth discussion explores the latest advancements in adjuvant kidney cancer treatment, focusing on the recent phase 3 trial results of Belzuti...
Episode 482: ASCO GU 2026 - SUNRISE 2
28 Feb 2026
Contributed by Lukas
The conversation revolves around the Sunrise 2 trial, a study investigating the efficacy of TAR-200 combined with cetrilimab versus traditional chemor...
Episode 483: ASCO GU 2026 - KEYNOTE B15: Neoadjuvant EVP vs Gem/Cis in Cis-eligible MIBC
27 Feb 2026
Contributed by Lukas
In this podcast , Brian, Tom and Matt Galsky discuss the B15 study data on neoadjuvant therapy for muscle invasive bladder cancer, focusing on the eff...
Episode 480: ASCO GU 2026 - PEACE-3 and BRCAway Final OS Results
26 Feb 2026
Contributed by Lukas
In this episode, Evan Yu discusses the latest prostate cancer data presented at ASCO GU, focusing on the final overall survival results of the PEACE 3...
Episode 479: Does the Timing of IO Infusion Impact Clinical Outcomes? A Critical Analysis
23 Feb 2026
Contributed by Lukas
This episode critically examines a recent Nature Medicine paper on the timing of immune therapy infusion in lung cancer, exploring the scientific plau...
Episode 478: Prostate Cancer Working Group 4 (PCWG 4) criteria
16 Feb 2026
Contributed by Lukas
SummaryThis Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group criteria, highlighting the iterative proc...
Episode 477: Uromigos Japan - GU Oncology 2025を総括!
11 Feb 2026
Contributed by Lukas
3人で前立腺癌、腎癌、尿路上皮癌の2025をレビューしました。
Episode 476: ASCO GU 2026 Preview
09 Feb 2026
Contributed by Lukas
In this podcast , the Uromigos discuss the upcoming ASCO GU conference. They delve into the latest research findings, including phase 3 trials, combin...
Episode 475: Depth of Response and Overall Survival for IO-based Regimens in mRCC: Results of an FDA Analysis
02 Feb 2026
Contributed by Lukas
In this Uromigos podcast episode, Brian and Tom engage with Elaine Chang from the FDA to discuss an analysis of depth of response as an indicator of s...
Episode 474: Uromigos Shorts - IO-refractory Urothelial Cancer
26 Jan 2026
Contributed by Lukas
In this episode of the YUromigospodcast, Brian Rini, Tom Powles, and Karine Tawagi discuss the complexities of immunotherapy re-challenge in bladder c...
Episode 473: Uromigos Shorts - EMBARK and BCR Prostate Cancer
19 Jan 2026
Contributed by Lukas
In this podcast, the Brian, Tm and David Einstein discuss the EMBARK study and its implications for patients with biochemically relapsed prostate canc...
Episode 472: Uromigos Shorts - Variant Histology Bladder Cancer
12 Jan 2026
Contributed by Lukas
This podcast discusses the significance of variant histology in urothelial cancer, emphasizing the need for tailored treatment approaches based on his...
Episode 471: Uromigos Shorts - ADCs and BiTEs in Prostate Cancer
05 Jan 2026
Contributed by Lukas
In this podcast, Brian and Tom engage with Pedro Barata to discuss the emerging field of bispecific T cell engagers and antibody-drug conjugates (ADCs...
Episode 470: Bladder Cancer Year in Review
29 Dec 2025
Contributed by Lukas
Tom, Brian and Silke discuss the blockbuster 2025 for urothelial cancer
Episode 469: Prostate Cancer year in Review
22 Dec 2025
Contributed by Lukas
Silke details the 2025 prostate cancer highlights
Episode 468: RCC Year in Review
15 Dec 2025
Contributed by Lukas
Brian, Tom and Silke discuss the highlights of RCC for 2025
Episode 467: The Uromigos Score for MIBC and Advanced Urothelial Cancer
09 Dec 2025
Contributed by Lukas
Matt Galsky joins to discuss the latest iteration of the Uromigos Score in Bladder Cancer. This score quantifies the clinical value of various approac...
Episode 442: The History of ARPI Development in Prostate Cancer
24 Nov 2025
Contributed by Lukas
Michael Morris from MSKCC joins us for an in-depth review of ARPI development across the spectrum of prostate caner
Episode 466: #UromigosLive 2025 - Novel Therapy in mRCC
10 Nov 2025
Contributed by Lukas
Brian and Tom tag team moderate this session which covers combination data, VEGF/PD1 bispecifics, microbiome approaches, cellular therapy and enrichme...
Episode 465: #UromigosLive 2025 - Adjuvant Therapy in RCC
10 Nov 2025
Contributed by Lukas
Tom leads the panel discussion about this evolving space including the RAMPART data and the press release about pembro/belzu.
Episode 464: #UromigosLive 2025 - The Evolving Landscape of mHSPC
10 Nov 2025
Contributed by Lukas
Brian moderates a panel of Chris Sweeney, Tanya Dorff, Mike Morris, Neeraj Aggarwal and Chuck Ryan as they discus and debate the mHSPC space with many...
Episode 459: #UromigosLive 2025 - Radioligands in Prostate Cancer
08 Nov 2025
Contributed by Lukas
Brian leads a discussion of Rana McCay, Chris Sweeney and Michael Morris on the PSMAddition data and the landscape of radioligands in prostate cancer....
Episode 458: #UromigosLive 2025 - Mock ODAC
08 Nov 2025
Contributed by Lukas
Brian takes the role of the FDA and we conduct a mock ODAC on the CREST and POTOMAC data
Episode 463: #UromigosLive 2025 Tres Uramigas: Resumen de la sesión sobre cáncer de vejiga metastásico
08 Nov 2025
Contributed by Lukas
Hay vida más allá de EV Pembro. Los Dres Durán, Gómez de Liaño y Coca Membribes repasan el estudio de DV-Toripalimab presentado recientemente en ...
Episode 462 #UromigosLive 2025: Tres Uramigas - Resumen de la sesión sobre cáncer de vejiga músculo-invasivo
08 Nov 2025
Contributed by Lukas
Los Dres Duran, Gómez de Liaño y Coca Membribes repasan el escenario perioperatorio en cáncer de vejiga músculo infiltrante. En cisplatino ineldgi...
Episode 461: #UromigosLive 2025 -Uromigos Japan - ウロミーゴズライブ2025: 筋層浸潤膀胱がんセッションの振り返り
08 Nov 2025
Contributed by Lukas
IMvigor011試験など最新の臨床データをもとに、ctDNAを用いた周術期治療戦略についての最前線をエキスパートが語...
Episode 460 #UromigosLive 2025: Uromigos Japan - ウロミーゴズライブ2025: 転移性膀胱がんセッションの振り返り
08 Nov 2025
Contributed by Lukas
ADCが転移性膀胱がん治療にもたらすインパクトをテーマに、RC48-C16試験など最新エビデンスをJun Guo先生をはじめ...
Episode 457: #UromigosLive 2025: ADCs in Bladder Cancer
07 Nov 2025
Contributed by Lukas
Tom moderates Jun Guo, Matt Galsky, Michiel Van der Heidjen and Shilpa Gupta as they discuss this ever-expanding class of agents in bladder cancer.
Episode 456: #UromigosLive 2025: Peri-operative Therapy for Urothlial Cancer
07 Nov 2025
Contributed by Lukas
The first session from UromigosLive 2025! In this episode, Tom moderates as Jonathan Rosenberg, Matt Galsky, Kala Sridhar and Josh Meeks discuss the p...
Episode 455: ESMO 2025 Urothelial Cancer Review
23 Oct 2025
Contributed by Lukas
Tom and Brian discuss the bladder cancer highlights from ESMO 2025. Show throwing is discussed.
Episode 454: ESMO 2025 Prostate and Kidney Cancer Review
23 Oct 2025
Contributed by Lukas
Silke, Tom and Brian discuss the prostate and RCC highlights from ESMO 2025
Episode 453: ESMO 2025 - IMvigor011
20 Oct 2025
Contributed by Lukas
Alex Wyatt joins us to discuss Tom's IMvigor011 data and the field of ctDNA
Episode 452: ESMO 2025 - DV+ toripalimab in bladder cancer
19 Oct 2025
Contributed by Lukas
Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.
Episode 451: ESMO 2025 - PSMAddition
19 Oct 2025
Contributed by Lukas
Scott Tagawa discusses his ESMO Presidential presentation on Lu-PSMA-617 in patients with mHSPC
Episode 450: ESMO 2025 - CAPITELLO
19 Oct 2025
Contributed by Lukas
Elena Castro describes the CAPITELLLO prostate cancer trial and her analysis from ESMO 2025
Episode 449: ESMO 2025 - ENZARAD
19 Oct 2025
Contributed by Lukas
Paul Nguyen and Chris Sweeney double team the ENZARAD data and put it into context with other data including STAMPEDE
Episode 448: Neoadjuvant EV/Pembro in Cis-ineligible MIBC
18 Oct 2025
Contributed by Lukas
Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. More applause!!
Episode 447: ESMO 2025 - RAMPART
18 Oct 2025
Contributed by Lukas
James Larkin joins to discuss adjuvant durva/treme vs observation in high risk resected RCC
Episode 446: ESMO 2025 - OPTIC and front-line RCC triplets
18 Oct 2025
Contributed by Lukas
Cristina Rodriguez joins us to discuss her data on front-line triplets, and we also discuss the prospective RNAseq-based biomarker OPTIC study
Episode 445: ESMO 2025 - Systemic Checkpoint Inhibition plus BCG in NMIBC (POTOMAC and ALBAN)
17 Oct 2025
Contributed by Lukas
Brad McGregor joins us on the heels of his #ESMO25 discussion of these important data in the NMIBC landscape.
Episode 444: ESMO 2025 Preview - Prostate and Renal Cancer
08 Oct 2025
Contributed by Lukas
Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025
Episode 443: ESMO 2025 Bladder Cancer Preview
02 Oct 2025
Contributed by Lukas
Tom and Brian preview the practice-changing bladder cancer data to be presented at ESMO 2025 in Berlin
Episode 441: The History of IO in Urothelial Cancer - Part 2
29 Sep 2025
Contributed by Lukas
Jonathan Rosenberg returns to finish this two-part series on IO drug development in urothelial cancer
Episode 440: The History of IO in Urothelial Cancer - Part 1
22 Sep 2025
Contributed by Lukas
Jonathan Rosenberg joins in this 2-part series on the history of IO-based therapy in Urothelial Cancer
Episode 439: Transcriptome Expression and Treatment Sensitivity in Prostate Cancer
15 Sep 2025
Contributed by Lukas
Gert Attard joins the show to discuss his recent Cell publication looking at tumor transcriptome-wide expression classifiers in advanced prostate canc...
Episode 438: The History of Testis Cancer Treatment
08 Sep 2025
Contributed by Lukas
Christian Kollmannsberger joins us to walk through decades of advances in advanced testis cancer.
Episode 437: Uromigos Japan - バルバーサ (Erdafitinib)を実臨床でどう使うか！
01 Sep 2025
Contributed by Lukas
Erdafitinibがついに承認されましたが、依然として多くのCQが残されています。日常診療に役立つ最新のデータをも...
Episode 436: The History of IO in RCC - Part 2
25 Aug 2025
Contributed by Lukas
We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.
Episode 435: The History of IO in RCC - Part 1
18 Aug 2025
Contributed by Lukas
The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.
Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC
04 Aug 2025
Contributed by Lukas
Danny Heng joins to tour through VEGF TKI drug development from sorafenib to tivozanib and everything in between.
Episode 433: Uromigos Japan - 改訂版ASCO mCRPCガイドライン
01 Aug 2025
Contributed by Lukas
5月に改訂されたASCOのmCRPC薬物療法のガイドラインについて3人でディスカッションしました！！評価はいかに？
Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap
21 Jul 2025
Contributed by Lukas
Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.
Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials
14 Jul 2025
Contributed by Lukas
Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can ...
Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers?
07 Jul 2025
Contributed by Lukas
Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program a...
Episode 429: ASCO2025レポート
02 Jul 2025
Contributed by Lukas
ASCO2025の注目演題を取り上げ解説、ディスカッションしました！
Episode 428: ASCO 2025 Recap
16 Jun 2025
Contributed by Lukas
Brian, Tom and Silke discuss their highlights form ASCO 2025
Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC)
13 Jun 2025
Contributed by Lukas
Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.
Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC
06 Jun 2025
Contributed by Lukas
Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025
Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI
04 Jun 2025
Contributed by Lukas
Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone
Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session
02 Jun 2025
Contributed by Lukas
Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.
Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC
01 Jun 2025
Contributed by Lukas
Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
Episode 422: ACSO 2025 - ctDNA data from NIAGARA
01 Jun 2025
Contributed by Lukas
Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.
Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer
01 Jun 2025
Contributed by Lukas
Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.
Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer
01 Jun 2025
Contributed by Lukas
Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation
Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study
31 May 2025
Contributed by Lukas
Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.
Episode 418: ASCO 2025 - Biomarkers in RCC
31 May 2025
Contributed by Lukas
David McDermott joins us on the heels of his outstanding discussion of the clinical science symposium on RCC biomarkers.
Episode 417: ASCO25 GUの注目演題について3人でDiscussion！！
24 May 2025
Contributed by Lukas
Practice Changing? 独断と偏見で選んだ注目演題について結果の予想も含めて議論しました。
Episode 416: ASCO 2025 Preview
19 May 2025
Contributed by Lukas
Silke, Tom and Brian discuss what they are looking forward to at ASCO 2025
Episode 415: Uromigos Score 前立腺がん編
12 May 2025
Contributed by Lukas
日本と海外の違いはあるのか？mHSPCとmCRPCのUromigos Scoreについて激論！！
Episode 414: Uromigos score en cáncer de próstata metastasico - más allá de las guías clínicas
12 May 2025
Contributed by Lukas
Edición especial en castellano con Alfonso Gómez de Liaño y Guillermo de Velasco. David Lorente da su visión sobre el nuevo Uromigos Score, que cl...
Episode 413: The Uromigos Score for Advanced Prostate Cancer
12 May 2025
Contributed by Lukas
Silke and Chris joins us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. S...
Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC
05 May 2025
Contributed by Lukas
Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC
Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMUIBC from SunRISe-1
05 May 2025
Contributed by Lukas
Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around...
Episode 411: Live from EIKCS in Amsterdam - RCC Highlights
03 May 2025
Contributed by Lukas
Viktor Grunwald joins to discuss the new data session from EIKCS
Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in high-risk NMIBC
26 Apr 2025
Contributed by Lukas
Neal Shore joins the show to discuss these exciting data from the American Urological Association Annual Meeting
Episode 408: Uromigos Japan - European Delphi Study of mRCCについてdiscussion
23 Apr 2025
Contributed by Lukas
今月Eur Urol OncolにPublishされたヨーロッパのエキスパートによるmRCCのコンセンサスについて日本との違いについて...
Episode 407: Drug Development in China: Part 2 of 2
21 Apr 2025
Contributed by Lukas
Part 2 of our series dives deeper into the explosion of ADC clinical drug development in China
Episode 406: Drug Development in China: Part 1 of 2
14 Apr 2025
Contributed by Lukas
Drs. Dingwei Ye and Yao Zhu from China join the show to talk about drug development in China amid the recent surge of GU clinical trials.
Episode 405: The Good News About Cancer podcast
11 Apr 2025
Contributed by Lukas
Drs. Alicia Morgans and Chuck Ryan join the show to talk about their new podcast.
Episode 404: 177 Lu-PSMA Pre-chemotherapy in mCRPC. Final Podcast from the Canary Islands
07 Apr 2025
Contributed by Lukas
Elena Castro joins Tom and Brian on the day after Pluvicto approval pre-chemotherapy in the US to discuss the PSMA Fore data and application in clinic...
Episode 403: ADCs in Bladder Cancer. Part 2 from the Canary Islands
02 Apr 2025
Contributed by Lukas
Ignacio Duran continues his discussion with Brian and Tom regarding novel ADCS in bladder cancer
Episode 402: Uromigos en Espanol: Futuro del carcinoma de células renales
31 Mar 2025
Contributed by Lukas
Cristina Suárez analiza los próximos ensayos clínicos que podrían transformar el manejo del cáncer renal en los próximos años: nuevas combinaci...
Episode 401: ADCs in Bladder Cancer. Part 1 from the Canary Islands
29 Mar 2025
Contributed by Lukas
Ignacio Duran joins the show to discuss the landscape of established ADCs in urothelial cancer and challenges of drug development in this setting.
Episode 400: The Uromigos Score for Urothelial Cancer
28 Mar 2025
Contributed by Lukas
Live from the Canary Islands 'Big Idea' talk from Tom, we discuss the new Uromigos Score which ranks different treatment options in several ur...
Episode 399: A PD1/VEGF Bispecific in Lung Cancer - Lessons for GU Cancers?
24 Mar 2025
Contributed by Lukas
Dr. John Heymach from MD Andersons joins us to discuss a novel PD1/VEGF bispecific agent in lung cancer and if there are applicaitons in GU malignanci...
Episode 398: Reflections on the Felix Feng Symposium at ASCO GU
17 Mar 2025
Contributed by Lukas
Chuck Ryan joins us to discuss his interview with Felix and reflects on his keynote address at ASCO GU 2025.
Episode 397: APCCC Diagnostics Conference recap
10 Mar 2025
Contributed by Lukas
Silke Gillessen joins us to discuss the top areas of consensus and controversy from APCCC 2025
Episode 396: Uromigos Japan - 激論 @JSMO25
09 Mar 2025
Contributed by Lukas
尿路上皮癌と腎癌の臨床に影響を与えるエビデンスをどう解釈するか!?
Episode 395: Uromigos Japan: ASCO GU 2025のレビュー
03 Mar 2025
Contributed by Lukas
ASCOGU2025で発表された臨床試験の結果の解釈について忖度なしに議論しました！！
Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025
01 Mar 2025
Contributed by Lukas
Tyler Seibert from UCSD joins the show live from Lugano to discuss meeting highlights and controversies (and his favorite run along the water..)